ProCE Banner Activity

GIMEMA LAL1811: Phase II Study of Frontline Ponatinib + Steroids in Elderly or Unfit Patients With Ph+ ALL

Slideset Download
Conference Coverage
Ponatinib combined with steroids yielded a 90% complete hematologic response and reasonable tolerability profile at Week 24 in unfit and elderly patients with Philadelphia chromosome–positive ALL.

Released: December 20, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology